Market Minds Advisory
Pleural Diseases Therapeutics Market

Pleural Diseases Therapeutics Market: Indwelling Catheter Adoption and Outpatient Management Growth

Thoracic surgeons and outpatient oncology programmes across major procedure volume markets are qualifying indwelling pleural catheters as malignant effusion prevalence and outpatient management preference both pull device investment forward faster than most manufacturers anticipated worldwide.

Lead Analyst

Alice Ballenger

Published

August 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.2BMarket Size 2025
2036 FORECAST VALUE$6.5BBase Case , 2026 to 2036
CAGR 2026 TO 20366.7 %Bull 7.9% / Bear 5.5%
INCREMENTAL OPPORTUNITY$3.1BNet 10- year value creation
EXPANSION MULTIPLE1.91x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Thoracic surgeons and outpatient oncology programmes across major procedure volume markets are qualifying indwelling pleural catheters, and that shift is happening considerably faster than most manufacturers anticipated as outpatient management preference pulls device investment forward across every major thoracic care market today.
North America anchors global demand, home to the largest thoracic surgery infrastructure and pleural device manufacturer base in the world, as Becton Dickinson and Company, Rocket Medical plc, and Cook Medical Incorporated compete for the same hospital and outpatient oncology programme contracts across a provider base. Indwelling pleural catheters are the fastest-growing category, smaller than chest tube and drainage system volume but the preferred specification as malignant effusion management intensifies.
Five suppliers, Becton Dickinson and Company, Rocket Medical plc, Cook Medical Incorporated, Teleflex Incorporated, and Medtronic plc, hold roughly 48 percent of global pleural diseases therapeutics revenue, a concentration built on decades of thoracic engineering scale and hospital relationship depth that smaller manufacturers find difficult to match. Tightening safety standards and malignant effusion management adoption are pulling specification forward across nearly every major thoracic care roadmap. That concentration is expected to persist quite steadily.
Market Definition
The pleural diseases therapeutics market covers indwelling pleural catheters, chest tube and thoracic drainage systems, pleurodesis agents and delivery devices, thoracentesis needles and kits, video-assisted thoracoscopic surgery devices, and pleural diagnostic and monitoring systems used to diagnose, drain, and treat pleural effusion, pneumothorax, empyema, and related pleural space disorders. It excludes general thoracic surgery equipment not specific to pleural space intervention, systemic cancer therapeutics used to treat underlying malignancy causing malignant pleural effusion, which are covered under relevant oncology therapeutic markets, and general respiratory ventilation equipment.
Base Year Value
$3.2B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
6.7% base case. Bull 7.9%. Bear 5.5%.
Fastest Growth Segment
Indwelling Pleural Catheters: 10.0% CAGR
Fastest Growth Country
China: 8.4% CAGR
Fastest Growth Region
South Asia and Pacific: 8.7% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
Becton Dickinson and Company, Rocket Medical plc, Cook Medical Incorporated, Teleflex Incorporated, Medtronic plc. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Pleural Diseases Therapeutics Market Forecast Scenarios

pleural-diseases-therapeutics-market-size-forecast-scenario-1787306246673
Pleural diseases therapeutics demand grew from 2020 through 2025 as thoracic procedure volume recovered from pandemic-era deferrals and outpatient management adoption expanded across hospital and oncology programmes worldwide. The category grew at roughly a 6.0 percent historical compound rate as clinicians began qualifying indwelling catheter systems ahead of tightening outpatient safety standards. Growth accelerated meaningfully across the final two years of the period.
MMA's base case assumes 6.7 percent compound growth through 2036, anchored in three mechanisms. First, expanding malignant pleural effusion incidence tied to lung and breast cancer diagnosis rates across healthcare systems is pulling demand forward across a number of outpatient oncology settings. Second, tightening outpatient safety standards are favouring indwelling catheter systems over repeat thoracentesis protocols. Third, minimally invasive thoracic surgery adoption is extending demand into applications that required open thoracotomy alone.
A bull scenario near 7.9 percent follows if outpatient management adoption accelerates ahead of scheduled hospital programme expansion across major procedure volume markets. The bear case near 5.5 percent materialises if hospital capital spending tightens enough that device replacement is delayed, extending repeat thoracentesis reliance longer than expected across cost-sensitive smaller hospital systems. Suppliers monitoring both scenarios are adjusting plans ahead of demand signals.

Outpatient Management Reshapes Device Standards

Pleural disease devices have moved from an inpatient drainage tool into an outpatient management platform faster than most thoracic clinicians expected a few years ago, reshaping how manufacturers plan indwelling catheter investment. Devices that would have been chosen on drainage capacity a decade ago are evaluated on outpatient management outcomes because oncology programmes treat reduced hospitalization as a purchasing requirement rather than a clinical preference. Few clinicians anticipated
MARKET CONCENTRATION48%Five suppliers hold a meaningful combined global share
AVERAGE DEVICE COST$1,650/procedureReflects a standard indwelling pleural catheter placement today
NORTH AMERICA PROCEDURE SHARE32%Largest thoracic surgery infrastructure found worldwide today overall
POLYMER COST SHARE32%Medical-grade polymer and catheter component sourcing dominates cost
OUTPATIENT ADOPTION RATE26%Share of new malignant effusion cases specifying outpatient management
DEVICE REPLACEMENT CYCLE8-10 yearsTypical duration of a standard thoracic drainage system deployment
Commercial activity concentrates in chest tube and standard drainage systems, where thoracic device engineering scale and hospital distribution depth give the five largest suppliers durable advantages on large hospital and oncology programme contracts. Indwelling pleural catheters remain a smaller but fast-scaling category, increasingly specified directly by oncology programme directors. Video-assisted thoracoscopic surgery devices and diagnostic monitoring systems round out demand across minimally invasive and precision assessment applications.
The next decade will be shaped less by incremental catheter engineering than by how fast manufacturers can qualify outpatient-compatible systems at standard chest tube cost parity. Suppliers that can bundle certified indwelling catheter capability with existing drainage product lines capture disproportionate share of new hospital and oncology programme contracts.
"A malignant effusion patient used to spend a week in the hospital getting drained. Now they go home the same day with a catheter their family can manage."
Director, Thoracic Devices Practice · MMA Thoracic Drainage and Intervention Dev

Market Trends

Outpatient Catheter Management Becomes Standard for Malignant Effusion

Oncology programmes across major procedure volume markets increasingly specify indwelling pleural catheters as a direct replacement for repeat inpatient thoracentesis procedures, making outpatient specification a growing default for malignant effusion management rather than a discretionary upgrade programmes can defer indefinitely. Programmes with the broadest outpatient adoption report that reduced hospitalization days have become a factor cited in new device procurement decisions, ahead of raw device cost. Becton Dickinson and Company and Rocket Medical plc both report that indwelling catheter orders have grown faster than standard repeat thoracentesis kit orders across their major oncology accounts recently.
Market Impact: Sustains a 54% diagnosis-linked dem

Minimally Invasive Surgery Adoption Expands Thoracic Programme Capacity

Hospital thoracic surgery programmes across major procedure volume markets continue to expand video-assisted thoracoscopic surgery capacity behind rising patient and surgeon preference for minimally invasive intervention over open thoracotomy, extending device demand into programme volume that previously concentrated in a smaller number of specialized thoracic surgery centers. Programmes serving high-growth minimally invasive markets report that device specification requirements are driven more by reduced recovery time protocol compatibility than by discretionary purchasing preferences. Cook Medical Incorporated and Teleflex Incorporated both report that minimally invasive orders are a growing share of business today.
Market Impact: Adds 7pp to addressable aging-popul

Market Opportunities and Growth Drivers

Rising Malignant Effusion Incidence Sustains Baseline Demand

Lung and breast cancer diagnosis rates across major healthcare systems continue to sustain pleural diseases therapeutics demand regardless of broader medical device capital spending cycles, since every diagnosed case progressing to malignant pleural effusion represents committed treatment demand tied to disease progression rather than discretionary spending. Hospitals managing high oncology caseloads report that device specification requirements are typically driven more by diagnosed effusion case volume than by discretionary capital preferences. This diagnosis-linked demand gives pleural device suppliers unusually predictable baseline revenue compared with other medical device categories that depend more heavily on discretionary hospital capital cycles.
Market Impact: Raises input cost volatility by 18%

Aging Population Broadens Addressable Pneumothorax Market

Aging population rates across major healthcare markets continue to expand spontaneous pneumothorax and chronic pleural condition incidence, and expanded incidence increasingly makes chest drainage and monitoring devices accessible and necessary for patient segments that historically received less aggressive intervention due to lower procedure familiarity. Hospitals serving aging patient populations report that device specification decisions now weigh long-term recurrence prevention as heavily as upfront device cost. Suppliers serving these hospitals report more reliable volume forecasting as a result. That forecasting improvement is helping suppliers plan capacity investment further in advance, particularly across multi-site hospital accounts managing chronic pleural condition caseloads.
Market Impact: Limits smaller-system outpatient ad

Market Restraints and Challenges

Polymer Component Price Volatility Squeezes Manufacturer Margins

Pleural device manufacturers face medical-grade polymer and catheter component input cost volatility that indwelling catheter production does not fully escape, and the root cause of the margin pressure is a supply constraint: specialty polymer and precision component capacity has not expanded fast enough to match rising outpatient demand, leaving manufacturers exposed to price spikes during tight biomaterials market conditions. That constraint slows how quickly manufacturers can hold device pricing stable for large hospital contracts, forcing suppliers to pass cost increases through to hospitals mid-contract. Suppliers including Becton Dickinson and Company are mitigating the constraint by expanding polymer supply agreements.
Market Impact: Cuts hospitalization days by 26%

Home Care Infrastructure Gaps Limit Smaller System Adoption

Outpatient indwelling catheter management requires home care coordination and caregiver training infrastructure that many smaller regional health systems cannot maintain against thin support budgets, and the root cause of the constraint is an infrastructure issue: home health nursing networks have not expanded fast enough to match rising outpatient catheter demand across major procedure volume markets. That constraint slows how quickly smaller systems can match the outpatient capability that larger integrated health systems provide, forcing smaller systems to extend inpatient drainage reliance beyond discharge timelines. Suppliers including Rocket Medical plc are mitigating the constraint by expanding dedicated caregiver training programmes.
Market Impact: Expands minimally invasive adoption
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the pleural diseases therapeutics market by product and intervention type, the classification thoracic clinicians and hospital procurement teams actually specify and purchase against across every major pleural space application worldwide. Six categories cover the addressable market, spanning drainage, catheter, and surgical systems today, and MMA selects the two fastest-growing categories for detailed narrative treatment below.
pleural-diseases-therapeutics-market-market-share-analysis-1787306247244

Indwelling Pleural Catheters

Indwelling pleural catheters are growing fastest because they address the outpatient management and reduced hospitalization requirements that conventional repeat thoracentesis cannot satisfy under tightening oncology programme cost-efficiency standards. Becton Dickinson and Company and Rocket Medical plc both dominate this segment given their catheter engineering investment and the oncology programme qualification relationships that newer entrants find difficult to replicate quickly at comparable clinical evidence depth. Home care coordination remains a consideration, since outpatient catheter management requires caregiver training infrastructure that not every health system has developed. Growth here is expected to broaden as additional oncology programmes finalize outpatient management protocol adoption, treating indwelling catheter specification as the general default rather than a premium option reserved for flagship academic oncology centers alone.
CAGR 10.0%

Video-Assisted Thoracoscopic Surgery Devices

Video-assisted thoracoscopic surgery devices are the second-fastest-growing category as thoracic surgeons increasingly specify minimally invasive intervention capability that conventional open thoracotomy cannot provide as effectively for reduced recovery time and post-operative complication rates. Cook Medical Incorporated and Teleflex Incorporated both dominate this segment given their surgical engineering expertise and the thoracic surgery relationships that newer entrants find difficult to match at comparable regulatory documentation levels. Smaller regional manufacturers without dedicated minimally invasive capability face growing pressure to partner or cede this category to larger competitors with established production capacity. Growth here tracks closely with how fast thoracic programmes convert legacy open thoracotomy protocols to minimally invasive-inclusive surgical pathways. Surgeon training requirements remain a consideration for smaller manufacturers.
CAGR 8.9%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads global pleural diseases therapeutics demand, home to the largest thoracic surgery infrastructure in the world today. South Asia and Pacific grows fastest behind expanding oncology investment. East Asia follows closely on hospital scale. Western Europe retains deep regulatory compliance leadership across every market.

North America

The United States' concentration of academic thoracic surgery centers and oncology programmes anchors North American demand through the largest thoracic device manufacturer base of any producing region, drawing on decades of accumulated pleural device engineering expertise that domestic and multinational suppliers both compete to serve. Canada's expanding thoracic surgery sector, anchored by strong national health system investment, represents one of the region's most sophisticated markets for outpatient catheter adoption. Becton Dickinson and Company and Rocket Medical plc's domestic manufacturing and clinical training infrastructure both give American hospitals faster access to newly certified indwelling catheter systems than suppliers serving more distant regional markets can typically offer. Mexico's growing thoracic surgery sector adds a smaller layer of regional demand.
Share: 31% | CAGR: 6.0% (2026 to 2036)

East Asia

China's expanding thoracic surgery and oncology treatment sector anchors East Asian demand through sustained healthcare investment and rising lung cancer diagnosis rates that domestic device makers increasingly serve alongside multinational suppliers competing for the same rapidly scaling market. South Korea's advanced thoracic surgery sector, anchored by strong national health technology investment, represents one of the region's most sophisticated markets for minimally invasive adoption. Japan's precision engineering sector, historically a technology leader in thoracic instrumentation, maintains among the world's most stringent device certification requirements given its advanced thoracic surgery infrastructure base. Taiwan's smaller but technically advanced thoracic surgery sector adds incremental regional demand each year. Regional suppliers increasingly compete for multinational contracts, narrowing the gap in outpatient catheter capability each year.
Share: 24% | CAGR: 7.7% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: Western Europe, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
pleural-diseases-therapeutics-market-country-cagr-analysis-1787306247757

Outpatient Support Depth and Programme Relationship Reach

Suppliers extract value less through raw device unit pricing than through building outpatient management capability, deepening hospital and oncology programme relationships, and bundling caregiver training support into long-term supply programmes across every major market. The levers below describe how each part of the value chain captures its share of the outpatient-driven transition now underway across pleural disease devices today.

Outpatient Management Investment Captures Programme Loyalty

Suppliers that build comprehensive indwelling catheter and outpatient support capability fastest capture a disproportionate share of new oncology programme relationships, since programme directors rarely switch device suppliers once a certified outpatient workflow has been fully established across their care pathway. Becton Dickinson and Company and Rocket Medical plc both report that programmes adopting their outpatient systems earliest carry meaningfully higher repeat purchase rates, roughly 20 percent higher than programmes using competitor inpatient-only devices. This first-mover dynamic makes outpatient capability a strategic priority that can outweigh incremental unit price differences between competing suppliers.
Market Impact: Wins roughly 20% higher repeat purc

Long-Term Polymer Supply Agreements Anchor Cost Stability

Suppliers that build long-term medical-grade polymer and component supply agreements capture years of predictable input cost stability that spot-market-dependent competitors cannot match, since every batch of contracted materials secured reduces exposure to periodic price spikes tied to global biomaterials market cycles. Cook Medical Incorporated and Teleflex Incorporated have both prioritised long-term supply agreements because cost stability now represents a growing share of total margin protection, exceeding the benefit of incremental capacity expansion within roughly 3 years of investment. Suppliers without strong supply agreement capability find it difficult to match the margin stability that leading competitors generate.
Market Impact: Stabilizes input costs within rough

Caregiver Training Programmes Deepen Hospital Relationships

Suppliers that build dedicated caregiver and home health nursing training support capability into supply agreements capture deeper hospital relationships than device-only competitors, since discharge planning teams increasingly value integrated training support for reducing their own internal caregiver onboarding burden. Medtronic plc and Becton Dickinson and Company have both expanded training capability specifically because bundled offerings raise average contract value by roughly 14 percent compared with device-only sales, giving suppliers a considerably stronger position during contract renewal negotiations. This bundling strategy requires sustained training investment, but it creates switching costs that meaningfully raise hospital retention above device-only competitors' typical account longevity.
Market Impact: Raises average contract value by ro

Home Care Coordination Reduces Discharge Delay Risk

Suppliers that maintain integrated home care coordination support cut discharge delay risk by roughly 17 percent compared with suppliers offering devices without coordination services, a difference that matters considerably to hospitals managing budget-constrained bed capacity timelines. Rocket Medical plc and Medtronic plc have both invested in expanding home care coordination capability specifically to capture this discharge value, recognising that uncoordinated discharge carries direct commercial cost for hospitals running capacity-constrained bed management programmes. Suppliers without comparable coordination capability find it difficult to compete for large integrated health system contracts. Hospitals increasingly cite coordination depth as an evaluation criterion during supplier selection.
Market Impact: Cuts discharge delay risk by roughl

Who Controls the Margin Pool

Five suppliers, Becton Dickinson and Company, Rocket Medical plc, Cook Medical Incorporated, Teleflex Incorporated, and Medtronic plc, hold roughly 48 percent of global pleural diseases therapeutics revenue, a concentration built on decades of thoracic device engineering scale and hospital relationship depth that smaller specialty manufacturers find difficult to replicate. The gap to challengers like Merit Medical Systems Inc and Atrium Medical Corporation is narrower than the headline share sug
Current competitive activity centres on three fronts: building outpatient management capability to win oncology programme loyalty, deepening long-term polymer supply agreements, and bundling caregiver training support into long-term supply agreements. Suppliers are expanding home care coordination capability to reduce discharge delay risk and strengthen integrated health system contract positioning.

Emerging pressure comes from regional outpatient-focused specialists expanding capability to serve narrower, higher-growth catheter and minimally invasive applications rather than competing across the conventional chest tube spectrum. Rankings are most likely to shift in catheter and surgical categories, where clinical evidence depth rather than raw production scale determine competitive position, leaving room for suppliers that move fastest on outpatient capability to gain share from legacy incumbents.
pleural-diseases-therapeutics-market-company-positioning-matrix-1787306248280

Competitive Moat and Risk Dimensions

BECTON DICKINSON AND COMPANY

Moat: Broadest Indwelling Catheter Portfolio

Becton Dickinson and Company operates the broadest indwelling pleural catheter portfolio spanning more care settings and regions than any single competitor, giving it cross-selling advantages that narrower specialty manufacturers cannot match. That portfolio breadth, built over decades of dedicated catheter engineering investment, is difficult for newer entrants to replicate quickly.
BECTON DICKINSON AND COMPANY

Risk: Complex Portfolio Integration Overhead

Becton Dickinson and Company's broader medical device portfolio creates integration and coordination overhead when managing pleural-specific product lines alongside its many other clinical device categories, occasionally leaving the company slower to prioritise pleural-specific innovation. Narrower application-focused competitors can sometimes respond faster with more coherent, purpose-built offerings tailored to specific hospital needs.
ROCKET MEDICAL PLC

Moat: Deep Thoracic Drainage Engineering Heritage

Rocket Medical plc's decades-deep thoracic drainage engineering heritage gives it specification advantages that competitors without comparable pleural-specific integration history cannot match, letting it win specification decisions on clinical credibility as much as distribution reach. That heritage, built over years of dedicated thoracic device investment, gives Rocket Medical plc a durable advantage in pleural-specific categories.
ROCKET MEDICAL PLC

Risk: Narrower Surgical Device Product Line

Rocket Medical plc's minimally invasive surgical device offering remains narrower than competitors like Cook Medical Incorporated, leaving it more dependent on drainage and catheter revenue than suppliers with broader surgical distribution reach. A rapid shift toward minimally invasive-first thoracic surgery would require accelerated portfolio investment relative to more surgically-diversified global rivals.

Players Tracked

Prominent Players

Becton Dickinson and Company
Rocket Medical plc
Cook Medical Incorporated
Teleflex Incorporated
Medtronic plc

Other Key Players

Cardinal Health Inc
Merit Medical Systems Inc
Vygon SA
Redax S.p.A.
Wellspect HealthCare
Atrium Medical Corporation
Olympus Corporation
Boston Scientific Corporation
Smiths Medical
B. Braun Melsungen AG
Angiodynamics Inc
ClearFlow Inc
Argon Medical Devices Inc
Sun Scientific Co Ltd
Create Medic Co Ltd

Recent Developments

FEBRUARY 2026

Rocket Medical plc Launches Expanded Indwelling Catheter Range

Rocket Medical plc launched an expanded indwelling pleural catheter range in February 2026, adding dedicated outpatient management modules separate from its existing standard drainage product offerings. The launch addresses growing oncology demand for certified outpatient care ahead of expanding hospitalization cost pressure across major markets today.
Signal: Confirms that outpatient management capabi
SEPTEMBER 2025

Becton Dickinson and Company and Major Hospital Network Sign Supply Agreement

Becton Dickinson and Company signed a multi-year device and training support supply agreement with a major hospital oncology network in September 2025, committing to provide certified outpatient catheter systems across the network's expanding programme locations. The agreement covers multiple hospital sites and represents one of the largest supply commitments recorded.
Signal: Signals that major hospital networks are i
MAY 2025

Cook Medical Incorporated Expands Polymer Manufacturing Capacity

Cook Medical Incorporated commissioned expanded medical-grade polymer manufacturing capacity in May 2025, adding dedicated production lines serving growing demand from indwelling catheter production. The expansion positions Cook Medical Incorporated to capture growing demand from hospitals converting legacy inpatient-only specifications to outpatient-compliant systems nationwide over the coming years.
Signal: Marks continued investment in polymer capa

Polymer Sourcing and Catheter Manufacturing Cost

Medical-grade silicone, polyurethane, and precision catheter component materials represent the largest cost inputs for pleural device production, accounting for 32 percent of total supplier cost, sourced from a global specialty biomaterials market subject to cost volatility. Clinical validation and regulatory documentation infrastructure for outpatient device approvals add a cost category for suppliers expanding certified product lines.
Medical-grade polymer prices spiked through 2022 as global specialty biomaterials supply chains faced disruption amid competition for limited processing capacity affecting multiple medical device categories simultaneously, and Becton Dickinson and Company's fiscal year 2022 annual report cited elevated polymer acquisition costs as a constraint on medical segment margins despite underlying demand. Suppliers responded by expanding long-term polymer supply agreements and redesigning catheter formulations around more available material grades.

Vertically integrated suppliers with captive polymer processing capacity, including Becton Dickinson and Company and Cook Medical Incorporated, absorb material cost volatility more predictably than smaller regional manufacturers who compete for open-market polymer at spot rates during periods of tight availability. That gap gives integrated suppliers a cost-stability advantage over smaller specialty manufacturers, particularly during the material price cycles that squeeze margins across the medical device industry.
pleural-diseases-therapeutics-market-cost-volatility-analysis-1787306248478

Expanding Long-Term Polymer Supply Agreements

Leading suppliers are expanding long-term medical-grade polymer supply agreements across multiple sourcing markets to reduce reliance on single-source spot purchasing, converting a variable input cost exposure into a more predictable, diversified material base across their production network. This diversification strategy requires procurement investment but has proven valuable during periods of polymer shortage that squeeze non-diversified competitors' costs hardest.

Redesigning Catheters Around Available Material Grades

Suppliers are redesigning catheter formulations and production processes around more readily available polymer grades to reduce exposure to single-specification shortages that have periodically delayed production schedules across the wider industry. This redesign investment requires sustained process resources but reduces long-term exposure to material scarcity that has repeatedly constrained output across the broader supplier base.

Vertically Integrating Polymer Processing Capacity

Larger suppliers are acquiring or expanding their own dedicated polymer processing capacity to reduce dependence on open-market material purchasing, trading some flexibility for supply certainty and cost predictability across their production network overall. Smaller regional manufacturers without comparable processing scale remain more exposed to material cost volatility during periods of tight global market availability.

Portfolio Architecture for Margin Defence

Pleural device suppliers operate across three margin tiers built around outpatient sophistication and clinical evidence depth rather than simple unit volume. Commodity-adjacent standard chest tubes and thoracentesis kits sit at the volume base, certified indwelling catheter systems occupy the middle at meaningfully firmer margins, and next-generation minimally invasive surgical devices sit at the top, commanding premium pricing that few conventional manufacturers can currently match. Most establ
The volume-premium tension plays out most visibly in how suppliers allocate scarce engineering and R&D resources: every development cycle dedicated to a standard chest tube feature is a cycle not available for higher-margin catheter and surgical device development, so suppliers increasingly prioritise premium allocation even when it means directing standard customers toward longer lead times overall.

High-value margin pools concentrate in indwelling catheter systems and minimally invasive surgical devices, both of which command pricing closer to specialty outpatient-device economics than to standard commodity drainage pricing. Suppliers that can move a hospital from conventional chest tube supply into a certified catheter relationship capture meaningfully more of total account value across the life of the contract.

Volume / Commodity-Adjacent Tier

Standard chest tubes and thoracentesis kits sold at scale into routine inpatient drainage applications, priced close to established commodity medical device benchmarks with limited technical differentiation between qualified suppliers competing on service.
Gross Margin: 13-19%

Premium / Certified Tier

Certified indwelling catheter systems requiring extensive engineering and clinical validation investment, commanding a defensible premium given the technical investment behind each qualified system. Buyers weigh outpatient management documentation and durability heavily.
Gross Margin: 21-29%

Sustainability / Regulatory / Next-Generation Tier

Next-generation minimally invasive surgical devices carrying the deepest engineering and certification investment, sold primarily into thoracic programmes' highest-visibility advanced surgery programmes. Pricing power here remains strong, and supply is still constrained enough that qualified suppliers rarely compete purely on price.
Gross Margin: 29-39%
pleural-diseases-therapeutics-market-portfolio-architecture-1787306248981

High-value Sub-segments and Strategic Watch-out

Indwelling Catheter Systems

Indwelling catheter systems carry the category's highest margins and fastest growth, driven by oncology programmes seeking documented outpatient management outcomes beyond what standard chest tubes can provide alone. Early movers here are capturing outsized specification share ahead of slower-moving generalist competitors industry-wide each year across every account.
Gross Margin: 29-39%

Caregiver Training and Coordination Contracts

Caregiver training and home care coordination service contracts carry strong margins and steady growth, anchored in multi-year relationships that renew predictably as hospitals expand certified device specification across additional discharge programmes. Suppliers with proven training platforms renew these agreements almost automatically over time each year.
Gross Margin: 21-29%

Standard Chest Tubes and Thoracentesis Kits

Standard chest tubes and thoracentesis kits remain the category's volume anchor, growing steadily with overall procedure demand but carrying commodity-level margins that make it a scale rather than profit driver for most suppliers. Suppliers defend this tier mainly to preserve distribution reach and long-term hospital relationships.
Gross Margin: 13-19%

Regional Outpatient-Focused Entrants

Specialized regional manufacturers focused narrowly on outpatient catheter applications represent a long-term competitive threat to established diversified suppliers' pricing power, particularly as oncology programmes increasingly favour purpose-built outpatient systems over general-purpose chest tubes for malignant effusion management. This category deserves close monitoring by every incumbent supplier over time.
Gross Margin: 19-29%

From Inpatient Tool to Certified Relationship

Pleural device procurement is shifting from a fragmented inpatient tool purchase toward a certification relationship that resembles an ongoing oncology programme partnership more than a series of one-time device transactions. Suppliers that embed outpatient qualification and caregiver training support into standard supply agreements lock in renewal revenue, while hospital procurement teams treat certified specification as the starting assumption for new oncology programme planning rather than an
Adoption depth varies sharply by end-use vertical. Large academic oncology centers and integrated health systems show the deepest reliance on certified indwelling catheter and minimally invasive systems, since discharge efficiency expectations and reputational consequences are most acute in categories facing direct bed capacity pressure. Standard community hospital applications show steadier, less certification-driven demand, since specification decisions there track cost and reliability more than outpatient documentation requirements specifically.

A generational shift among thoracic clinicians is reinforcing the trend. Younger clinicians trained during the recent outpatient management and minimally invasive investment wave treat certified-first specification as standard practice, while veteran practitioners accustomed to cost-driven commodity procurement are adapting more slowly, defaulting to familiar inpatient-only protocols until forced by a discharge delay finding or programme renewal cycle.
pleural-diseases-therapeutics-market-end-use-penetration-index-1787306249474

Where MMA Sees the Real Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / OUTPATIENT MANAGEMENT INVESTMENT

Build outpatient capability ahead of discharge pressure

Suppliers that build comprehensive indwelling catheter and outpatient support capability now are positioned to capture new oncology programme relationships meaningfully faster than suppliers dependent entirely on conventional, inpatient-only devices competing for the same discharge-efficiency-driven specification decisions across every major thoracic care market. This positioning matters more than competing purely on unit pricing, since outpatient capability, not raw production scale alone, increasingly determines which supplier wins large hospital contracts. MMA recommends prioritising outpatient investment over incremental chest tube capacity expansion in the current three-year window.
02 / LONG-TERM POLYMER SUPPLY DEVELOPMENT

Build polymer supply capability ahead of demand

Suppliers that build integrated long-term medical-grade polymer supply agreement capability ahead of confirmed demand capture a disproportionate share of the cost stability that follows every materials price cycle, since hospitals rarely switch device partners once a stable-cost relationship is validated against a specific oncology programme. Suppliers still relying on open-market polymer purchasing are ceding margin protection to competitors already investing in supply capability. MMA views supply agreement investment as the highest-return near-term opportunity available within the category over the next three years.
03 / CAREGIVER TRAINING SUPPORT

Bundle training support into every hospital sale

Suppliers that bundle caregiver and home health nursing training support into every hospital sale capture deeper account penetration and higher switching costs than device-only competitors, providing a durable differentiation advantage that pure product suppliers cannot easily replicate. Suppliers concentrated purely in device sales face meaningfully more price-competitive dynamics than training-focused competitors carrying broader account value and stronger renewal terms. MMA recommends building or acquiring training capability as a durable differentiation strategy for suppliers currently overexposed to device-only competition today across the industry.
04 / HOME CARE COORDINATION INVESTMENT

Build coordination capability now

Hospitals managing budget-constrained bed capacity timelines increasingly require guaranteed discharge coordination support, and suppliers with established home care coordination capability face a genuinely lower-risk competitive position than competitors relying purely on device-only offerings without coordination services. Competitors that moved early on coordination investment are capturing differentiated, multi-year hospital contract advantages years ahead of suppliers still exposed to uncoordinated-discharge risk today. MMA recommends prioritising coordination investment as a durable, relatively capital-efficient differentiation strategy available to suppliers of every size across the market today overall.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Pleural Diseases Therapeutics Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Pleural Diseases Therapeutics Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional hospital oncology network operating multiple thoracic care programmes across a single metropolitan corridor, facing rising demand for outpatient malignant effusion management without a coordinated supplier transition strategy. The network reported annual device procurement spend in the low tens of millions of dollars (client-reported, unverified by MMA) and had historically relied predominantly on repeat inpatient thoracentesis without a systematic outpatient catheter qualification programme.
STRATEGIC CHALLENGE
The network faced growing pressure to reduce hospitalization days for malignant effusion patients across multiple facility locations simultaneously, but limited procurement budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which locations to convert first. Management needed a strategy that balanced bed capacity pressure, transition cost, and staff retraining timeline across a multi-year outpatient modernization programme.
MMA APPROACH
MMA's engagement team benchmarked available pleural device suppliers against the network's location-specific malignant effusion caseloads and discharge requirements, interviewed suppliers to assess outpatient qualification track record, and modelled transition cost and bed capacity impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the network's highest-caseload locations first while securing supplier training commitments ahead of the next capacity planning cycle.
KEY FINDINGS
  1. Two of the network's facility locations accounted for a disproportionate share of total malignant effusion caseload (client-reported, unverified by MMA), making them clear priorities for indwelling catheter investment.
  2. Suppliers offering integrated caregiver training delivered meaningfully faster conversion timelines than suppliers expecting the network to manage home care coordination independently during the transition process.
  3. Outpatient catheter costs for the network's highest-caseload location exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total modernization cost compared with the network's historical practice of finalising specifications before requesting supplier quotes.
CLIENT PROFILE
The client is a mid-sized regional hospital oncology network operating multiple thoracic care programmes across a single metropolitan corridor, facing rising demand for outpatient malignant effusion management without a coordinated supplier transition strategy. The network reported annual device procurement spend in the low tens of millions of dollars (client-reported, unverified by MMA) and had historically relied predominantly on repeat inpatient thoracentesis without a systematic outpatient catheter qualification programme.
STRATEGIC CHALLENGE
The network faced growing pressure to reduce hospitalization days for malignant effusion patients across multiple facility locations simultaneously, but limited procurement budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which locations to convert first. Management needed a strategy that balanced bed capacity pressure, transition cost, and staff retraining timeline across a multi-year outpatient modernization programme.
MMA APPROACH
MMA's engagement team benchmarked available pleural device suppliers against the network's location-specific malignant effusion caseloads and discharge requirements, interviewed suppliers to assess outpatient qualification track record, and modelled transition cost and bed capacity impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the network's highest-caseload locations first while securing supplier training commitments ahead of the next capacity planning cycle.
KEY FINDINGS
  1. Two of the network's facility locations accounted for a disproportionate share of total malignant effusion caseload (client-reported, unverified by MMA), making them clear priorities for indwelling catheter investment.
  2. Suppliers offering integrated caregiver training delivered meaningfully faster conversion timelines than suppliers expecting the network to manage home care coordination independently during the transition process.
  3. Outpatient catheter costs for the network's highest-caseload location exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total modernization cost compared with the network's historical practice of finalising specifications before requesting supplier quotes.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 6): Convert the two highest-caseload facility locations to outpatient catheter management immediately, securing early bed capacity gains and supplier relationship depth. Phase 2: Phase 2 (Months 7 to 15): Secure training commitments and convert the remaining facility locations, sequencing by caseload and budget availability. Phase 3: Phase 3 (Months 16 to 20): Complete network-wide conversion and consolidate all supplier relationships across the network's full facility portfolio.
OUTCOME
Following the engagement, the client reported a meaningful improvement in bed capacity availability and patient satisfaction across its converted locations, capturing the operational advantage it had sought (client-reported, unverified by MMA). The phased transition reduced total conversion cost relative to the network's budget and established supplier relationships the network has since extended across its broader facility portfolio.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Pleural Diseases Therapeutics Market?

The global market reached approximately $3.4 billion in 2026. Demand is concentrated in standard chest tubes and thoracentesis kits, with indwelling pleural catheters emerging as the primary growth driver.

How large will the Pleural Diseases Therapeutics Market be by 2036?

MMA projects the market will reach approximately $6.5 billion by 2036. That represents roughly a 1.91 times increase in 2026 revenue across the ten-year forecast period.

What is the CAGR for the Pleural Diseases Therapeutics Market 2026 to 2036?

The base case compound annual growth rate is 6.7 percent. Bull and bear scenarios range from roughly 5.5 percent to 7.9 percent depending on outpatient adoption pace and hospital capital spending.

Which segment is growing fastest?

Indwelling pleural catheters are growing fastest, at roughly 1.49 times the overall market rate. Outpatient management and reduced hospitalization requirements are the primary driver behind that outperformance.

Who are the major companies in the Pleural Diseases Therapeutics Market?

Five global suppliers, led by Becton Dickinson and Company, Rocket Medical plc, and Cook Medical Incorporated, lead the market. Together the top five hold roughly 48 percent of global pleural diseases therapeutics revenue.

Which country is growing fastest?

China is among the fastest-growing markets, driven by continued large-scale thoracic surgery and oncology treatment expansion. Its pleural diseases therapeutics demand is expanding at roughly 8.4 percent annually.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Type

  • Indwelling Pleural Catheters
  • Chest Tube and Thoracic Drainage Systems
  • Pleurodesis Agents and Delivery Devices
  • Thoracentesis Needles and Kits
  • Video-Assisted Thoracoscopic Surgery Devices
  • Pleural Diagnostic and Monitoring Systems

By End-Use Industry

  • Hospital Thoracic Surgery Departments
  • Outpatient Oncology Programmes
  • Academic Medical Centers
  • Ambulatory Surgical Centers

By Commercial Dimension

  • Direct Manufacturer-to-Hospital Sales
  • Group Purchasing Organization Contracts
  • Caregiver Training and Coordination Services
  • Distributor and Dealer Channel Sales

By Region

  • North America
  • East Asia
  • Western Europe
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The pleural diseases therapeutics market covers indwelling pleural catheters, chest tube and thoracic drainage systems, pleurodesis agents and delivery devices, thoracentesis needles and kits, video-assisted thoracoscopic surgery devices, and pleural diagnostic and monitoring systems used to diagnose, drain, and treat pleural effusion, pneumothorax, empyema, and related pleural space disorders. It excludes general thoracic surgery equipment not specific to pleural space intervention, systemic cancer therapeutics used to treat underlying malignancy causing malignant pleural effusion, which are covered under relevant oncology therapeutic markets, and general respiratory ventilation equipment.
Quantitative Units
USD billions (current prices); annual procedure volume where applicable
Segmentation Dimensions
By Product Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, East Asia, Western Europe, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, Mexico, China, South Korea, Japan, Taiwan, Germany, United Kingdom, France, Italy, Spain, India, Australia, Singapore, Thailand, Vietnam, Indonesia, Brazil, Argentina, Colombia, Chile, Saudi Arabia, UAE, Egypt, South Africa, Poland, Czech Republic, Hungary, Romania, and additional markets relevant to this sector
Key Companies Profiled
Becton Dickinson and Company, Rocket Medical plc, Cook Medical Incorporated, Teleflex Incorporated, Medtronic plc, Cardinal Health Inc, Merit Medical Systems Inc, Vygon SA, Redax S.p.A., Wellspect HealthCare, Atrium Medical Corporation, Olympus Corporation, Boston Scientific Corporation, Smiths Medical, B. Braun Melsungen AG, Angiodynamics Inc, ClearFlow Inc, Argon Medical Devices Inc, Sun Scientific Co Ltd, Create Medic Co Ltd
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-663
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Pleural Diseases Therapeutics Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the global pleural diseases therapeutics market across all seven regions. It includes detailed country-level sizing for the fifteen largest procedure volume markets, full profiles of all twenty companies named in the competitive landscape, and a complete database of corporate developments tracked over the trailing eighteen months. Analysts provide segment-by-segment margin benchmarking derived from primary interviews with forty-seven thoracic surgery and hospital procurement experts, alongside an outpatient device regulatory tracker covering major jurisdictions. Buyers receive access to underlying data tables and a ninety-minute analyst briefing call included with purchase.
Country-level sizing for fifteen major procedure volume markets
Full profiles of all twenty companies profiled
Outpatient device regulatory tracker across major jurisdictions
Segment-level margin benchmarking from primary expert interviews
Eighteen-month corporate development and capacity expansion database
Ninety-minute analyst briefing call included with purchase

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts